Harden C
Comprehensive Epilepsy Center, Cornell Medical Center, New York, New York 10021, USA.
Epilepsia. 2001;42 Suppl 4:36-9.
Levetiracetam was approved in November 1999 as add-on therapy for the treatment of partial-onset seizures in adults (age 16 years and older). This review focuses on recently published data from four well-controlled studies in patients with partial-onset seizures with or without secondary generalization. When levetiracetam was given along with other antiepileptic drugs (AEDs), the most frequently reported adverse events were central nervous system related. Adverse events were usually mild to moderate in intensity, with the most frequently reported events occurring predominantly during the first 4 weeks of treatment. No relationship was apparent between the dose of levetiracetam and the most commonly reported adverse events in well-controlled clinical trials within the recommended dose range of 1,000-3,000 mg/day. Levetiracetam is a Pregnancy Category C drug. Overall, when used in combination with other AEDs, levetiracetam was generally well tolerated as add-on treatment for partial-onset seizures.
左乙拉西坦于1999年11月被批准作为辅助疗法用于治疗成人（16岁及以上）部分性发作癫痫。本综述聚焦于最近发表的四项针对有或无继发性全面发作的部分性发作患者的对照良好的研究数据。当左乙拉西坦与其他抗癫痫药物（AEDs）联用时，最常报告的不良事件与中枢神经系统相关。不良事件的强度通常为轻至中度，最常报告的事件主要发生在治疗的前4周。在1000 - 3000毫克/天的推荐剂量范围内，左乙拉西坦的剂量与对照良好的临床试验中最常报告的不良事件之间无明显关联。左乙拉西坦是C类妊娠用药。总体而言，与其他AEDs联合使用时，左乙拉西坦作为部分性发作癫痫的辅助治疗通常耐受性良好。
